Japan's No.1 in cardiovascular sales
We have the largest market share in the products for PCI (percutaneous coronary intervention), minimally invasive treatments for myocardial infarction and angina pectoris in Japan.
(Sales breakdown for FY2020)
Our speciality lies in minimally invasive treatments particularily heart treatments including PCI, CRS and CVS. 70% of group sales account for heart treatment related products.
Expanding to non-cardiac areas
Minimally invasive treatment field is now expanding from heart to other areas, including leg, brain, neck. Accordingly, we are expanding our product portfolio for diabetes treatment and brain surgery etc.